<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03651102</url>
  </required_header>
  <id_info>
    <org_study_id>TI</org_study_id>
    <nct_id>NCT03651102</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia</brief_title>
  <acronym>Thal-Thalido</acronym>
  <official_title>Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia Patients of Pakistan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blood Diseases Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blood Diseases Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thalidomide is known to have hypnosedative, immuno-modulatory and anti-angiogenic effects.
      The drug is widely used in several neoplastic disorders (e.g. multiple myeloma and malignant
      melanoma), inflammatory conditions (e.g. Crohn's disease) and skin disorders (e.g. leprosy).
      Thalidomide has been successfully used in adult thalassemia patients. The current study
      explores its role in younger thalassemia patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Haemoglobin Level</measure>
    <time_frame>6-24 months</time_frame>
    <description>mg/dL</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Thalassemia</condition>
  <arm_group>
    <arm_group_label>Patients Receiving Thalidomide Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All the study patients will be given thalidomide at an average dose of 2mg/kg/day (range 1-3mg/kg/day). The patients will be followed at 4 weeks interval by a haematologist for monitoring of potential side effects and for evaluation of clinical and laboratory response.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide Oral Product</intervention_name>
    <description>Dosage: 1-3mg/kg/day</description>
    <arm_group_label>Patients Receiving Thalidomide Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Transfusion dependent thalassemia patients

        Exclusion Criteria:

          -  Those with active systemic comorbidity, with past personal or family history of
             thrombophilia or history of splenectomy in the past 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhammad Tariq M Khan, MBBS, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Blood Diseases Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muhammad Tariq M Khan, MBBS, PhD</last_name>
    <phone>+92-300-5888867</phone>
    <email>drtariqmsd@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Muhammad Tariq H Khan, MBBS, MPhil</last_name>
    <phone>+92-333-9355661</phone>
    <email>.tariq_razmian@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Blood Diseases Clinic</name>
      <address>
        <city>Peshawar</city>
        <state>Khyber Pakhtukhwa</state>
        <zip>0000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Tariq M Khan</last_name>
      <phone>+92-300-5888867</phone>
      <email>drtariqmsd@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <reference>
    <citation>Li Y, Ren Q, Zhou Y, Li P, Lin W, Yin X. Thalidomide has a significant effect in patients with thalassemia intermedia. Hematology. 2018 Jan;23(1):50-54. doi: 10.1080/10245332.2017.1354427. Epub 2017 Jul 18.</citation>
    <PMID>28718348</PMID>
  </reference>
  <reference>
    <citation>Ren Q, Zhou YL, Wang L, Chen YS, Ma YN, Li PP, Yin XL. Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia. Ann Hematol. 2018 Oct;97(10):1933-1939. doi: 10.1007/s00277-018-3395-5. Epub 2018 Jun 22.</citation>
    <PMID>29931453</PMID>
  </reference>
  <reference>
    <citation>Masera N, Tavecchia L, Capra M, Cazzaniga G, Vimercati C, Pozzi L, Biondi A, Masera G. Optimal response to thalidomide in a patient with thalassaemia major resistant to conventional therapy. Blood Transfus. 2010 Jan;8(1):63-5. doi: 10.2450/2009.0102-09.</citation>
    <PMID>20104280</PMID>
  </reference>
  <reference>
    <citation>Ricchi P, Costantini S, Spasiano A, De Dominicis G, Di Matola T, Cinque P, Ammirabile M, Marsella M, Filosa A. The long-term and extensive efficacy of low dose thalidomide in a case of an untransfusable patient with Non-Transfusion-Dependent Thalassemia. Blood Cells Mol Dis. 2016 Mar;57:97-9. doi: 10.1016/j.bcmd.2016.01.003. Epub 2016 Jan 16.</citation>
    <PMID>26810455</PMID>
  </reference>
  <reference>
    <citation>Aguilar-Lopez LB, Delgado-Lamas JL, Rubio-Jurado B, Perea FJ, Ibarra B. Thalidomide therapy in a patient with thalassemia major. Blood Cells Mol Dis. 2008 Jul-Aug;41(1):136-7. doi: 10.1016/j.bcmd.2008.03.001. Epub 2008 Apr 24.</citation>
    <PMID>18439858</PMID>
  </reference>
  <reference>
    <citation>Chen J, Zhu W, Cai N, Bu S, Li J, Huang L. Thalidomide induces haematologic responses in patients with β-thalassaemia. Eur J Haematol. 2017 Nov;99(5):437-441. doi: 10.1111/ejh.12955. Epub 2017 Sep 27.</citation>
    <PMID>28850716</PMID>
  </reference>
  <reference>
    <citation>Fard AD, Hosseini SA, Shahjahani M, Salari F, Jaseb K. Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of β-Hemoglobinopathy Disorders. Int J Hematol Oncol Stem Cell Res. 2013;7(3):47-54. Review.</citation>
    <PMID>24505535</PMID>
  </reference>
  <reference>
    <citation>Gambari R. Foetal haemoglobin inducers and thalassaemia: novel achievements. Blood Transfus. 2010 Jan;8(1):5-7. doi: 10.2450/2009.0137-09. Review.</citation>
    <PMID>20104272</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 24, 2018</study_first_submitted>
  <study_first_submitted_qc>August 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Blood Diseases Clinic</investigator_affiliation>
    <investigator_full_name>Muhammad Tariq Masood Khan</investigator_full_name>
    <investigator_title>Consultant Haematologist; Research Associate</investigator_title>
  </responsible_party>
  <keyword>Thalidomide</keyword>
  <keyword>Thalassemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

